With last observations carried forward ( LOCF ) , mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID ( -16.2 ) and haloperidol ( -15.4 ) than placebo ( -10.7 ; both P < 0.05 ) ; using mixed model for repeated measures ( MMRM ) , changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID ( -21.3 and -19.4 , respectively ) and haloperidol ( -20.0 ) than placebo ( -14.6 ; all P < 0.05 ) .
O O O O O O O O O O O O O O O O O O O O O O O O O O B-ChemicalEntity O O O O O O O O B-ChemicalEntity O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-ChemicalEntity O O O O O O O O O O O O O O B-ChemicalEntity O O O O O O O O O O O O O O